Vivani Medical, Inc. said its wholly owned unit Cortigent, Inc. will merge with ClearOne, Inc., setting up the combined company for a new Nasdaq listing under the ticker CRGT. The transaction includes a concurrent financing and will reshape ownership across both firms, with Vivani expected to control the majority of the combined entity.
The deal, announced by the companies, centers on Cortigent’s brain-computer interface approach using precision neurostimulation. Cortigent’s product portfolio includes the Orion artificial vision system and a new platform aimed at restoring mobility after stroke.
Key takeaways
- Price move: ClearOne shares (CLRO) were last reported at $3.70, up 14.91%.
- Catalyst: A planned merger in which Cortigent becomes part of ClearOne, followed by a renaming and a new Nasdaq ticker (CRGT).
- Ownership implication: Vivani is expected to own 59.4% to 67.5% of the combined company, while former ClearOne shareholders are expected to hold 12.7% to 14.4%.
- Funding to accelerate pipeline: ClearOne will raise between $10 million and $15 million via concurrent financing to support Cortigent’s neurostimulation development.
What drove the move
ClearOne said Cortigent will be merged into the public company structure, with Cortigent becoming a wholly owned subsidiary of ClearOne. In connection with the transaction, ClearOne will be renamed Cortigent Holdings, Inc. and is expected to trade on Nasdaq under the new ticker CRGT. The announcement effectively reframes ClearOne’s corporate identity around Cortigent’s clinical-stage neurostimulation technology platform.
While Vivani is focused on its implantable drug delivery programs, the merger is designed to allow Cortigent to pursue development as a separate publicly listed company. Management said the move is intended to reduce Vivani’s direct operating expenditures and enable its team to concentrate on its drug implant portfolio, according to statements included in the announcement.
Deal structure and expected ownership
Under the agreement, Vivani will receive 12.5 million shares of ClearOne common stock. Based on the transaction terms described, Vivani is expected to own between 59.4% and 67.5% of the combined company after the merger. Former ClearOne shareholders are expected to hold between 12.7% and 14.4%, reflecting a transfer of control toward Vivani-backed assets.
At the same time, ClearOne will raise $10 million to $15 million through a concurrent financing. The companies said the additional capital is meant to accelerate development of Cortigent’s neurostimulation technologies, including its vision restoration efforts and stroke recovery device program.
How investors are likely to interpret the merger
The market reaction to mergers involving early-stage health technology companies often centers on capital availability and execution risk—particularly when development plans extend beyond near-term commercialization. Here, investors were presented with both a corporate reorganization and a financing pathway aimed at funding Cortigent’s pipeline, which includes technologies in artificial vision and post-stroke mobility support.
Cortigent CEO Jonathan Adams said the financing will help accelerate work on its neurostimulation technologies, including vision restoration and stroke recovery devices. Vivani CEO Adam Mendelsohn characterized the merger as years of work to bring Cortigent into a separate publicly listed structure, while also positioning Vivani to reduce direct expenditures related to Cortigent and focus on its drug implant programs.
For ClearOne shareholders, the deal represents an ownership dilution alongside a strategic pivot: the public listing would effectively shift from ClearOne’s prior identity to Cortigent’s technology platform. For Vivani, the exchange offers a path to transfer value into a dedicated vehicle while retaining majority control of the combined company.
Bigger picture: what to watch next
The companies are positioning the combined platform for a Nasdaq listing under CRGT, with the concurrent financing intended to support ongoing development. The immediate next steps for investors will likely involve confirmation of transaction timing, completion mechanics, and any regulatory or shareholder approvals required to implement the merger and ticker change.
Investors may also focus on how the companies describe milestones and how the financing proceeds will be allocated across Cortigent’s neurostimulation roadmap, particularly for the artificial vision system and the stroke recovery mobility device concept. With ClearOne shares having traded in a wide range over the past year—between $2.71 and $12.25—the announcement has introduced a new set of catalysts tied to biotech execution rather than ClearOne’s prior business outlook.
ClearOne shares were last reported at $3.70, up 14.91%, following the announcement, according to the reported market data in the release.
